Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone in Hospitalized Patients With COVID-19
NCT05713292Phase 3Completed
- Sponsor
- Capital Medical University
- Start
- Dec 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in COVID-19 pneumonia comparing Pirfenidone with Placebo (2 arms). Primary endpoint: Effect of pirfenidone on fibrotic signs induced by COVID19 infection at 1 month. Started Dec 2022; status: completed.
02
Drugs
pirfenidone
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT05713292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05713292.